ReviewMolecular neurobiology2026
Phytocompounds Targeting Signaling Pathways in Stroke: Preclinical and Clinical Insights into Therapeutic Mechanisms and Neurotoxicity.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke, primarily due to ischemic injury and neurodegeneration, is a significant global cause of death and permanent neurological impairment in adults. Phytocompounds are promising candidates for stroke care because of their effects on key molecular signaling pathways that promote neuroprotection in stroke. This review highlights the therapeutic potential of phytocompounds, such as curcumin, resveratrol, quercetin, berberine, and epigallocatechin gallate, which target signaling pathways, including PI3K/Akt, Nrf2/ARE, MAPK, NF-κB, and JAK/STAT. These substances have neuroprotective properties by managing oxidative stress, apoptosis, mitochondrial dysfunction, neuroinflammation, excitotoxicity, and blood-brain barrier integrity. Preclinical research has indicated that phytocompound therapy significantly decreases infarct volume, neuronal loss, and behavioral impairments. Despite strong experimental evidence, the clinical application of phytocompounds is limited by their low brain permeability, short half-life, poor bioavailability, and irregular dosages. Furthermore, demonstrating the neurotoxicity and safety profiles of phytocompounds is essential because of the potential risks, such as hepatotoxicity, genotoxicity, and brain transmission interference. Nanotechnology-based delivery methods, such as liposomes and phytocompound-loaded nanoparticles, have demonstrated the ability to overcome pharmacokinetic restrictions while reducing the toxicity. Phytocompounds that target various neuroprotective signaling pathways are potential supplements or alternative treatments for stroke. To ensure clinical efficacy and safety, it is essential to follow the recognized dosage guidelines, perform thorough neurotoxicity evaluations and conduct rigorous clinical studies. Future studies should explore the potential of phytocompounds in conjunction with traditional treatments and precision medicine techniques for personalized stroke care.
Indexed as
Identifiers
42310196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.